Asset profile
GSK4532990
Unknown / undisclosed
Evidence outlook · lead readout
NCT06104319 · Non-alcoholic Fatty Liver Disease
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06104319: The trial randomized participants among four GSK4532990 dose groups, but it was open-label, had no placebo or active comparator, and used biomarker expression rather than a clinical or endoscopic outcome as its primary endpoint. With no results posted, there is no reported primary-endpoint comparison to assess.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.